JP2021519269A5 - - Google Patents

Info

Publication number
JP2021519269A5
JP2021519269A5 JP2020551327A JP2020551327A JP2021519269A5 JP 2021519269 A5 JP2021519269 A5 JP 2021519269A5 JP 2020551327 A JP2020551327 A JP 2020551327A JP 2020551327 A JP2020551327 A JP 2020551327A JP 2021519269 A5 JP2021519269 A5 JP 2021519269A5
Authority
JP
Japan
Prior art keywords
oxide
alkyl
azaspiro
piperazine
carboxylate
Prior art date
Application number
JP2020551327A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183636A5 (https=
JP2021519269A (ja
JP7497294B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023916 external-priority patent/WO2019183636A1/en
Publication of JP2021519269A publication Critical patent/JP2021519269A/ja
Publication of JPWO2019183636A5 publication Critical patent/JPWO2019183636A5/ja
Publication of JP2021519269A5 publication Critical patent/JP2021519269A5/ja
Priority to JP2023214561A priority Critical patent/JP2024037979A/ja
Application granted granted Critical
Publication of JP7497294B2 publication Critical patent/JP7497294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551327A 2018-03-23 2019-03-25 ピペラジンアザスピロ誘導体 Active JP7497294B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023214561A JP2024037979A (ja) 2018-03-23 2023-12-20 ピペラジンアザスピロ誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647106P 2018-03-23 2018-03-23
US62/647,106 2018-03-23
PCT/US2019/023916 WO2019183636A1 (en) 2018-03-23 2019-03-25 Piperazine azaspiro derivaves

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023214561A Division JP2024037979A (ja) 2018-03-23 2023-12-20 ピペラジンアザスピロ誘導体

Publications (4)

Publication Number Publication Date
JP2021519269A JP2021519269A (ja) 2021-08-10
JPWO2019183636A5 JPWO2019183636A5 (https=) 2022-03-31
JP2021519269A5 true JP2021519269A5 (https=) 2022-03-31
JP7497294B2 JP7497294B2 (ja) 2024-06-10

Family

ID=66102243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551327A Active JP7497294B2 (ja) 2018-03-23 2019-03-25 ピペラジンアザスピロ誘導体
JP2023214561A Pending JP2024037979A (ja) 2018-03-23 2023-12-20 ピペラジンアザスピロ誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023214561A Pending JP2024037979A (ja) 2018-03-23 2023-12-20 ピペラジンアザスピロ誘導体

Country Status (14)

Country Link
US (2) US11524954B2 (https=)
EP (2) EP4219464A1 (https=)
JP (2) JP7497294B2 (https=)
CN (1) CN112154145B (https=)
AR (1) AR115015A1 (https=)
CA (1) CA3094366A1 (https=)
DK (1) DK3768669T3 (https=)
ES (1) ES2942837T3 (https=)
FI (1) FI3768669T3 (https=)
HU (1) HUE061533T2 (https=)
PL (1) PL3768669T3 (https=)
PT (1) PT3768669T (https=)
TW (1) TWI801540B (https=)
WO (1) WO2019183636A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219464A1 (en) * 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
KR20220079921A (ko) 2019-10-09 2022-06-14 노파르티스 아게 M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체
PE20221454A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
KR20210067005A (ko) * 2019-11-28 2021-06-08 제이투에이치바이오텍 (주) 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
EP4100410B1 (en) * 2020-02-05 2026-04-22 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
PE20242344A1 (es) 2021-05-12 2024-12-16 Boehringer Ingelheim Int DERIVADOS DE PIRIDINA CON SUSTITUYENTES CICLICOS LIGADOS A N COMO INHIBIDORES DE cGAS
WO2023010078A1 (en) * 2021-07-30 2023-02-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
KR20250086639A (ko) * 2022-09-16 2025-06-13 세레벨 쎄라퓨틱스, 엘엘씨 M4 활성제/조절제 및 이의 용도
EP4649077A1 (en) * 2023-01-12 2025-11-19 Cerevel Therapeutics, LLC Spiro derivatives as m4 activators/modulators and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
MXPA05013770A (es) 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
UY28538A1 (es) 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
JP2008543923A (ja) 2005-06-22 2008-12-04 ファイザー・プロダクツ・インク ヒスタミン−３受容体アンタゴニスト
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
US20070107917A1 (en) 2005-11-14 2007-05-17 Doherty Brian J Multifunctional robot tool
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
RS20080484A (sr) 2006-04-21 2009-07-15 Pfizer Products Inc., PIRIDIN[3,4-b] PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
KR102352388B1 (ko) * 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
WO2015140614A1 (en) 2014-03-21 2015-09-24 Align Technology, Inc. Segmented orthodontic appliance with elastics
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4219464A1 (en) * 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves

Similar Documents

Publication Publication Date Title
JP2021519269A5 (https=)
CA2661334C (en) Pyrimidone compounds as gsk-3 inhibitors
FI3768669T3 (fi) Piperatsiiniatsaspirojohdannaisia
US11319298B2 (en) Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
JP4782239B2 (ja) 異常細胞増殖治療のためのスルホニルアミド誘導体
US9636337B2 (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
US8586751B2 (en) Nicotinamide compounds useful as kinase modulators
JP2019523233A5 (https=)
US9637491B2 (en) Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
JP5823518B2 (ja) ブルトン型チロシンキナーゼの阻害剤
US9718804B2 (en) GSK-3 inhibitors
JP2018534326A5 (https=)
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2013544256A5 (https=)
KR20170131654A (ko) Usp30 억제제로서의 1-시아노-피롤리딘 화합물
SK3452003A3 (en) Pyridine derivatives with IKB-kinase (IKK-beta) inhibiting activity
RU2018142987A (ru) Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4
JP2015522002A5 (https=)
JP2013519701A (ja) ピペリジン誘導体
US20160016907A1 (en) Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
RU2015144386A (ru) Циклоалкилнитрилпиразолопиридоны в качестве ингибиторов янус-киназы
JPWO2019183636A5 (https=)
EP4676923A1 (en) Biarylamide derivatives and their use as pkmyt1 inhibitors
IL303563A (en) Heterocyclic derivatives P2X7 receptor antagonists
JP7796892B2 (ja) 二置換オクタヒドロピロロ［３，４－ｃ］ピロールメチルケトン誘導体及びその使用